Skip to main content

Table 4 Haemagglutination inhibition antibody immune responses against TIV strains (According To Protocol cohort for immunogenicity)

From: A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine

Strain Time point Group Na Seroconversion rate Seroprotection rate Geometric mean fold rise >2.5 Geometric mean titre
     Value or % [95% CIa]
A/Brisbane/59/2007 Day 21 A 92 77.2% [67.2-85.3%] 93.5% [86.3-97.6%] 8.4 [6.5-10.8] 145.1 [115.9-181.6]
  B 86 86.0% [76.9-92.6%] 97.7% [91.9-99.7%] 12.9 [10.0-16.6] 215.7 [168.2-276.5]
  C 92 82.6% [73.3-89.7%] 96.7% [90.8-99.3%] 12.0 [9.4-15.4] 226.3 [181.4-282.2]
  D 88 79.5% [69.6-87.4%] 92.1% [84.5-96.8%] 9.6 [7.7-12.1] 158.7 [127.9-197.1]
Day 42 E 91 18.7% [11.3-28.2%] 51.6% [40.9-62.3%] 2.3 [1.9-2.6] 32.9 [27.3-39.7]
  F 91 30.8% [21.5-41.3] 68.1% [57.5-77.5%] 3.2 [2.7-3.8] 53.2 [43.5-65.1]
Day 63 A 92 68.5% [58.0-77.8%] 91.3% [83.6-96.2%] 6.9 [5.4-8.9] 120.2 [96.5-149.7]
  B 86 88.4% [79.7-94.3%] 100% [95.8-100%] 11.2 [9.1-13.7] 186.5 [150.4-231.4]
  C 92 75.0% [64.9-83.4%] 92.4% [84.9-96.9%] 8.4 [6.6-10.6] 157.0 [126.0-195.8]
  D 88 72.7% [62.2-81.7%] 88.8%[80.3-94.5%] 7.6 [6.0-9.5] 124.3 [99.0-156.1]
  E 91 78.0% [68.1-86.0%] 89.0% [80.7-94.6%] 9.4 [7.6-11.7] 137.4 [109.0-173.1]
  F 91 83.5% [74.3-90.5%] 95.6% [89.1-98.8%] 10.1 [8.1-12.6] 166.9 [132.5-210.3]
Day 182 A 92 48.9% [38.3-59.6%] 68.5% [58.0-77.8%] 4.0 [3.1-5.3] 68.5 [53.6-87.4]
  B 89 64.0% [53.2-73.9%] 83.1% [73.7-90.2%] 5.2 [4.2-6.6] 89.2 [71.0-112.0]
  C 85 52.9% [41.8-63.9%] 77.6% [67.3-86.0%] 4.7 [3.7-6.0] 87.4 [68.5-111.5]
  D 89 43.2% [32.7-54.2%] 68.5% [57.8-78.0%] 3.7 [2.9-4.8] 64.6 [51.4-81.1]
  E 89 51.7% [40.8-62.4%] 75.3% [65.0-83.8%] 4.4 [3.5-5.4] 64.6 [51.4-81.1]
   F 91 59.3% [48.5-69.5%] 78.0% [68.1-86.0%] 5.0 [4.0-6.3] 83.7 [66.0-106.2]
A/Uruguay/716/2007 Day 21 A 92 78.3% [68.4-86.2%] 84.8% [75.8-91.4%] 17.4 [13.0-23.3] 175.7 [129.6-238.2]
  B 86 84.9% [75.5-91.7%] 89.5% [81.1-95.1%] 15.5 [11.8-20.4] 183.5 [135.2-248.9]
  C 92 78.3% [68.4-86.2%] 83.7% [74.5-90.6%] 20.6 [14.8-28.6] 181.7 [128.1-257.9]
  D 88 86.4% [77.4-92.8%] 88.8% [80.3-94.5%] 19.3 [14.2-26.4] 191.4 [138.4-264.7]
Day 42 E 91 3.3% [0.7-9.3%] 19.8% [12.2-29.4%] 1.2 [1.1-1.4] 12.5 [10.0-15.6]
  F 91 6.6% [2.5-13.8%] 30.8% [21.5-41.3%] 1.7 [1.5-1.9] 19.1 [15.6-23.4]
Day 63 A 92 77.2% [67.2-85.3%] 84.8% [75.8-91.4%] 13.3 [10.0-17.6] 134.4 [100.4-179.9]
  B 86 80.2% [70.2-88.0%] 87.2% [78.3-93.4%] 11.7 [9.1-15.0] 138.4 [104.8-182.7]
  C 92 75.0% [64.9-83.4%] 79.3% [69.6-87.1%] 15.0 [11.2-19.9] 132.0 [94.9-183.7]
  D 88 78.4% [68.4-86.5%] 84.3% [75.0-91.1%] 14.6 [10.9-19.6] 145.6 [107.7-196.8]
  E 91 82.4% [73.0-89.6%] 89.0% [80.7-94.6%] 20.8 [15.5-28.0 216.1 [160.0-292.0]
  F 91 85.7% [76.8-92.2%] 91.2% [83.4-96.1%] 19.3 [14.6-25.5] 221.9 [167.2-294.6]
Day 182 A 92 63.0% [52.3-72.9%] 71.7% [61.4-80.6%] 9.0 [6.7-11.9] 89.5 [65.8-121.8]
  B 89 62.9% [52.0-72.9%] 71.9% [61.4-80.9%] 7.2 [5.6-9.3] 87.7 [64.0-120.3]
  C 85 63.5% [52.4-73.7%] 70.6% [59.7-80.0%] 9.7 [7.2-13.1] 87.1 [61.4-123.5]
  D 89 63.6% [52.7-73.6% 71.9% [61.4-80.9%] 8.5 [6.2-11.7] 87.8 [63.4-121.4]
  E 89 67.4% [56.7-77.0%] 76.45 [66.2-84.85] 9.9 [7.3-13.5] 110.0 [79.3-152.6]
   F 91 67.0% [56.4-76.5%] 76.9% [66.9-85.1%] 10.6 [7.9-14.2] 127.2 [92.3-175.5]
B/Brisbane/60/2008 Day 21 A 92 82.6% [73.3-89.7%] 98.9% [94.1-100%] 12.6 [9.8-16.2] 662.1 [545.4-803.8]
  B 86 88.4% [79.7-94.3%] 98.8% [93.7-100%] 13.9 [11.1-17.5] 658.3 [540.2-802.0]
  C 92 80.4% [70.9-88.0%] 97.8% [92.4-99.7%] 10.5 [8.3-13.5] 478.8 [389.5-588.6]
  D 88 88.6% [80.1-94.4%] 100% [95.9-100%] 14.3 [11.0-18.7] 576.1 [479.8-691.8]
Day 42 E 91 6.6% [2.5-13.8%] 82.4% [73.0-89.65] 1.3 [1.1-1.5] 74.7 [61.4-90.9]
  F 91 26.4% [17.7-36.7%] 97.8% [92.3-99.7%] 2.4 [2.0-2.8] 139.5 [120.0-162.2]
Day 63 A 92 79.3% [69.6-87.1%] 98.9% [94.1-100%] 9.6 [7.5-12.4] 506.7 [422.3-608.0]
  B 86 84.9% [75.5-91.7%] 100% [95.8-100%] 10.0 [8.1-12.2] 471.2 [396.3-560.2]
  C 92 72.8% [62.6-81.6%] 98.9% [94.1-100%] 7.9 [6.3-9.9] 359.6 [299.4-431.9]
  D 88 83.0% [73.4-90.1%] 100% [95.9-100%] 10.8 [8.4-13.7] 433.5 [369.5-508.7]
  E 91 85.7% [76.8-92.2%] 100% [96.0-100%] 11.4 [9.1-14.2] 644.9 [534.5-778.2]
  F 91 83.5% [74.3-90.5%] 100% [96.0-100%] 11.9 [9.4-15.0] 688.1 [593.0-798.6]
Day 182 A 92 73.9% [63.7- 82.5%] 97.8% [92.4-99.7%] 6.7 [5.2-8.6] 339.9 [276.7-417.5]
  B 89 60.7% [49.7-70.9%] 98.9% [93.9-100%] 5.7 [4.5-7.1] 273.8 [228.7-327.9]
  C 85 56.5% [45.3-67.2%] 92.9% [85.3-97.4%] 5.5 [4.3-6.9] 245.4 [197.8-304.3]
  D 89 72.7% [62.2-81.7%] 100% [95.9-100%] 6.8 [5.3-8.6] 292.6 [247.0-346.7]
  E 89 75.3% [65.0-83.8%] 98.9% [93.9-100%] 6.9 [5.4-8.7] 369.6 [300.0-455.3]
   F 91 68.1% [57.5-77.5%] 100% [96.0-100%] 6.4 [5.0-8.1] 378.4 [323.4-442.8]
  1. a N = Number of subjects with available results.
  2. b LL = Lower limit.
  3. c CI = Confidence Interval.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us